

Serial No. 10/829,468
Attorney Docket No. 22305

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



ART UNIT:	1616
EXAMINER:	Ernst V. Arnold
APPLICANT:	Motyka et al.
SERIAL NO.:	10/829,468
FILED:	04/21/2004
CONFIRM. NO.:	6421
FOR:	NON-GMO METAL AMINO ACID CHELATES AND NON-GMO METAL AMINO ACID CHELATE-CONTAINING COMPOSITIONS

AMENDMENT/RESPONSE

**CERTIFICATE OF MAILING
UNDER 37 C.F.R. § 1.8**

DATE OF DEPOSIT: 3/3/06

I hereby certify that this paper or fee (along with any paper or fee referred to as being attached or enclosed) is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated above and is addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Brenda L. Wiseman
Signature

THORPE NORTH & WESTERN, LLP
8180 South 700 East, Suite 200
Sandy, Utah 84070

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The present amendments and remarks are in response to the November 3, 2005 Office Action where the Examiner rejected claims 1-51. Two terminal disclaimers and the fees therefore under 37 C.F.R. § 120(d) are enclosed herewith. A petition for a one month extension of time and the appropriate fee is enclosed herewith. Before reconsideration of the present Application, please enter this Amendment and consider the accompanying responsive remarks.

INTRODUCTORY COMMENTS FOR AMENDMENTS

Please amend the claims in the manner indicated below. In the following amendments, an underline is used to indicate added text, and strikeouts are used to indicate deleted text. Brackets may also be used for deleted text or characters when strikeouts are not sufficiently clear, e.g., such as striking out a hyphen. Claims 1 and 17 have been amended to clarify the point of novelty of the current invention. Specific support for claims 1 and 17 can be found in the specification on page 2, lines 20-21, and page 3, lines 15-19. Claims 5-10 have been amended to correct antecedent basis errors. Additionally, claims 10, 39, and 48 have been amended to clarify the ambiguity resulting from typographical errors as questioned by the Examiner. New claims 52 and 53 are fully supported by the specification as originally filed, as they include the amino acid to metal molar ranges set forth in claims 1 and 17 as originally filed. As the amendments to claims 1 and 17 are supported in the specification and the remaining amendments are entered to clarify antecedent basis issues and to fix typographical errors, no new matter has been added.